Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | JAK1 |
Variant | Q503* |
Impact List | nonsense |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | JAK1 Q503* results in a premature truncation of the Jak1 protein at amino acid 503 of 1154 (UniProt.org). Q503* is associated with resistance to immunotherapy (PMID: 27433843), but due to the loss of the protein kinase domains (UniProt.org), is predicted to lead to a loss of Jak1 protein function. |
Associated Drug Resistance | Y |
Category Variants Paths |
JAK1 mutant JAK1 inact mut JAK1 Q503* |
Transcript | NM_002227.4 |
gDNA | chr1:g.64855650G>A |
cDNA | c.1507C>T |
Protein | p.Q503* |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_002227 | chr1:g.64855650G>A | c.1507C>T | p.Q503* | RefSeq | GRCh38/hg38 |
NM_001321853.1 | chr1:g.64855650G>A | c.1507C>T | p.Q503* | RefSeq | GRCh38/hg38 |
NM_001320923 | chr1:g.64855650G>A | c.1507C>T | p.Q503* | RefSeq | GRCh38/hg38 |
NM_001321856.1 | chr1:g.64855650G>A | c.1507C>T | p.Q503* | RefSeq | GRCh38/hg38 |
NM_001321854 | chr1:g.64855650G>A | c.1507C>T | p.Q503* | RefSeq | GRCh38/hg38 |
NM_001321855 | chr1:g.64855650G>A | c.1507C>T | p.Q503* | RefSeq | GRCh38/hg38 |
NM_001321852.1 | chr1:g.64855650G>A | c.1507C>T | p.Q503* | RefSeq | GRCh38/hg38 |
NM_001321853.2 | chr1:g.64855650G>A | c.1507C>T | p.Q503* | RefSeq | GRCh38/hg38 |
XM_047419674.1 | chr1:g.64855650G>A | c.1507C>T | p.Q503* | RefSeq | GRCh38/hg38 |
NM_001321854.1 | chr1:g.64855650G>A | c.1507C>T | p.Q503* | RefSeq | GRCh38/hg38 |
NM_001321855.1 | chr1:g.64855650G>A | c.1507C>T | p.Q503* | RefSeq | GRCh38/hg38 |
NM_001320923.2 | chr1:g.64855650G>A | c.1507C>T | p.Q503* | RefSeq | GRCh38/hg38 |
NM_001321856 | chr1:g.64855650G>A | c.1507C>T | p.Q503* | RefSeq | GRCh38/hg38 |
NM_002227.3 | chr1:g.64855650G>A | c.1507C>T | p.Q503* | RefSeq | GRCh38/hg38 |
NM_001321856.2 | chr1:g.64855650G>A | c.1507C>T | p.Q503* | RefSeq | GRCh38/hg38 |
XM_047419675.1 | chr1:g.64855650G>A | c.1507C>T | p.Q503* | RefSeq | GRCh38/hg38 |
NM_001321852 | chr1:g.64855650G>A | c.1507C>T | p.Q503* | RefSeq | GRCh38/hg38 |
NM_001321852.2 | chr1:g.64855650G>A | c.1507C>T | p.Q503* | RefSeq | GRCh38/hg38 |
NM_001321855.2 | chr1:g.64855650G>A | c.1507C>T | p.Q503* | RefSeq | GRCh38/hg38 |
NM_001320923.1 | chr1:g.64855650G>A | c.1507C>T | p.Q503* | RefSeq | GRCh38/hg38 |
NM_002227.4 | chr1:g.64855650G>A | c.1507C>T | p.Q503* | RefSeq | GRCh38/hg38 |
NM_001321854.2 | chr1:g.64855650G>A | c.1507C>T | p.Q503* | RefSeq | GRCh38/hg38 |
NM_001321853 | chr1:g.64855650G>A | c.1507C>T | p.Q503* | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK1 Q503* | melanoma | predicted - resistant | Pembrolizumab | Case Reports/Case Series | Actionable | In a clinical study, a melanoma patient treated with Keytruda (pembrolizumab) initially demonstrated a partial response, however, post 419 days developed disease progression likely due to the secondary resistance mutation, JAK1 Q503* (PMID: 27433843). | 27433843 |